[June 21, 2016]

World Generic Markets Issue - More Work Necessary For WHO To Break Biosimilar Naming Stalemate - Research and Markets

Research and Markets has announced the addition of the "World Generic Markets Issue 280 (V15 I13)" report to their offering.

The issue of naming biosimilars and biologics in ways that enhances safety monitoring continues to be a contentious one; the generic industry is becoming increasingly implacable in its opposition to the WHO's Biological Qualifiers solution. Coupled with the US FTC's (News - Alert) anticompetitive concerns over the FDA's approach to naming, a growing stalemate is emerging. The WHO will need to spend more time on the issue if an acceptable pathway is to be created."

Key Topics Covered:

1. More Work Necessary For WHO To Break Biosimilar Naming Stalemate
2. Teva Canada Launches Abacavir+Lamivudine
3. Teva Compltes Rimsa Acquisition
4. Celgene Receives Paclitaxel ANDA Notice
5. Alvogen To Acquire County Line Pharmaceuticals
6. Aurobindo Gains US Acetylcysteine Approval
7. Legislation Will Tackle Price-Gouging Symptoms But Not Cause
8. Teva Launches Budesonide Inhalation Suspension
9. New US Approvals For Hikma
10. Fougera To Consolidate Two New York Facilities
11. ANI To Acquire Propranolol Assets From Cranford
12. Confluence Of ANDA Backlog And Pricing Issues Will Maintain Pressure On FDA
13. Teva Acquisition Of Allergan Generics Edges Closer With Key European Approval
14. EGA Changes Name To Medicines For Europe
15. Gedeon Richter Expands Debrecen Biotech Plant
16. Altan Enters Caspofungin Licensing Agreement
17. Dr Reddy's Enters Biosimilars Collaboration With TR-Pharm
18. Lupin On Course To Cement Place In US Market
19. Prevnar 13 Patent Attack Will Pressure Indian Patent Office
20. Debiopharm Sees Victory In Japanese Oxaliplatin Lawsuit
21. Aspen Will Look To Offset Foreign Currency Weaknesses

View source version on businesswire.com: http://www.businesswire.com/news/home/20160621006272/en/

[ Back To TMCnet.com's Homepage ]